comparemela.com

Latest Breaking News On - Brazilian national health surveillance agency anvisa - Page 1 : comparemela.com

Brazil: Federal Police Force Wants President Jair Bolsonaro Charged With Spreading Fake COVID-19 Information

A New Outbreak of C auris Has Been Reported in Brazil

28-year-old volunteer in AstraZeneca COVID-19 vaccine trial dies

28-year-old volunteer in AstraZeneca COVID-19 vaccine trial dies The trial has not been paused as the volunteer did not receive the COVID-19 vaccine but was part of the control group. , Managing Editor A volunteer in AstraZeneca s COVID-19 vaccine trial has died, according to Brazilian National Health Surveillance Agency Anvisa, and reported by Reuters. The volunteer was a 28-year-old physician who treated coronavirus patients in Rio de Janeiro, according to The Washington Post, citing Brazilian newspaper O Globo as its source. The volunteer did not receive the COVID-19 vaccine, but was in the control group. Half the people in the clinical trial received the experimental vaccine, and the other half received an established meningitis vaccine. The volunteer is believed to have received the meningitis vaccine. The cause of death has not been released.

Brazilian regulator to consider imports of Sputnik V on April 26

Brazilian regulator to consider imports of Sputnik V on April 26 Brazilian National Health Surveillance Agency will consider this possibility at the request of several states in the country © AP Photo/Eraldo Peres RIO DE JANEIRO, April 24. /TASS/. On April 26, Brazilian National Health Surveillance Agency (Anvisa) will consider the possibility of importing the Russian Sputnik V coronavirus vaccine at the request of several states in the country, according to the regulator s website. It was specified that the extraordinary meeting is scheduled for 18:00 local time (00:00 April 27 Moscow time). The Brazilian regulator explained the delays in considering the application for registration of Sputnik V by the lack of a complete set of documents for the drug.

Phase III data of CoronaVac to be released in Brazil, data showing good safety

Update: Sinovac s COVID-19 vaccine effective in Brazil trials, though results release postponed By Hu Yuwei, Leng Shumei and Xu Hailin Source: Global Times Published: 2020/12/23 20:09:52 Last Updated: 2020/12/23 23:21:26 Quality inspectors on Sinovac vaccine production lines use digital technology platforms to monitor the quality and efficiency of vaccine packaging on Sunday. Photos: Li Hao/GT The government of São Paulo announced on Wednesday that CoronaVac is over 50 percent effective, but has again postponed the release of detailed data on the effectiveness of the vaccine developed by the Sao Paulo-based Butantan Institute in partnership with the Chinese pharmaceutical company Sinovac. According to Dimas Covas, director of the Butantan Institute, the phase III study showed that the vaccine is effective.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.